Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT06008093
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT05883644
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 25
- Registration Number
- NCT05809869
- Locations
- 🇭🇰
Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong
SIRT With Tremelimumab and Durvalumab for Resectable HCC
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Jiping Wang, MD, PhD
- Target Recruit Count
- 20
- Registration Number
- NCT05701488
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 210
- Registration Number
- NCT05557838
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Durvalumab and Tremelimumab in Resectable HCC
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 28
- Registration Number
- NCT05440864
- Locations
- 🇮🇹
University of Milan, Milan, Italy
🇪🇸Clinica Universidad De Navarra, Pamplona, Spain
🇨🇦University Health Network, Toronto, Ontario, Canada
......SMARTEST Trial......
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 30
- Registration Number
- NCT05380713
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Himalaya Early Access Program
- Conditions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05345678
- Locations
- 🇺🇸
Research Site, Morgantown, West Virginia, United States
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 725
- Registration Number
- NCT05301842
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Target Recruit Count
- 40
- Registration Number
- NCT05239169
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt am Main, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.